The signal
The first gene-editing therapies have been approved for rare blood disorders. Trials are underway targeting more common conditions, including one-time treatments to permanently lower cholesterol.
Where it could lead
A one-time treatment for a common chronic disease would upend how medicine is delivered and paid for — shifting from lifelong pills to a single intervention.
Evidence that would strengthen the case
- Successful late-stage trials for a common disease
- Prices and payment models that make one-time cures affordable
- Treatments delivered by a simple injection rather than complex hospital procedures
What could prevent it
- Safety problems or unexpected long-term side effects
- Costs remain far too high for widespread use
- Public or regulatory backlash over editing genes